Pressroom
-
Coronavirus Treatments, Not Just Vaccines, Will Save Lives and Generate Value
Treatment for COVID-19 would deliver up to $106 billion in gains by the end of 2021 a new USC Schaeffer Center analysis finds.
Categorized in -
Older Adults Perceived Higher Risk of Dying From COVID-19, but Were More Optimistic in the Early Days of the U.S. Epidemic
A USC Schaeffer study examined age-related COVID-19 risk perception among more than 6,500 American adults.
Categorized in -
Schaeffer Study Shows Public Investment in Stem Cell Research Makes Economic Sense
Stem cell research holds promise for generating breakthroughs against conditions including Alzheimer’s, cancer, diabetes, heart disease, vision loss—and even COVID-19.
Categorized in -
Access to Medicare Insurance Coverage Linked to Reduction in Cancer Mortality
The findings show access to Medicare coverage increases cancer detection and reduces cancer mortality. Cancer detection increased by 10% at age 65 compared to people just one or two years younger.
Categorized in -
A Letter to RCMAR Scientists, Faculty, and Staff
This letter from June 8, 2020, was penned by 30 RCMAR directors to RCMAR scientists, faculty and staff.
Categorized in -
Survey Results Suggest the Importance of Clearly Communicating Coronavirus Risk and Behavior — Including as States Re-Open
Analysis of March survey data sheds light on our understanding of how perceptions of the virus impact behavior.
Categorized in -
A Testing Strategy to Get Americans Back to Work and School
A new USC Schaeffer Center white paper proposes an innovative strategy — pooled testing — that could lower COVID-19 testing costs for schools and businesses by half or more compared to frequent individual testing.
Categorized in -
Study Finds Surprise Medical Bills Springing from Ambulatory Surgery Centers
One-in-twelve episodes at ambulatory surgery centers had the potential to result in a surprise medical bill, according to the study.
-
Schaeffer Center Fellow Tapped for California COVID-19 Task Force
Schaeffer Center Nonresident Senior Fellow Bob Kocher will join the public-private effort, which is aiming for record-level testing across the state.
Categorized in -
New Study Explores Variation in Biosimilar Prescription Levels by Provider Type
The research suggests office-based providers are adopting biosimilars earlier and faster than hospital-based providers, indicating provider awareness, financial incentives and information-sharing might be important levers to examine further.
Categorized in